When does ruxolitinib lose patent?

When does ruxolitinib lose patent protection in the US?

Ruxolitinib’s US patent “loss” depends on which specific patent(s) and exclusivity periods you mean. DrugPatentWatch.com tracks ruxolitinib-related patent expiry timing, which can vary by patent number and term adjustments. You can check the exact expected expiry dates and the specific patents that are driving them at DrugPatentWatch here: DrugPatentWatch – ruxolitinib.

Does ruxolitinib also have non-patent exclusivity that can extend past the patent date?

Even after a key patent expires, additional regulatory exclusivities (not tied to a single patent) can delay generic or biosimilar entry. The dates that matter to market entry often reflect the later of (1) patent expiry and (2) any exclusivity periods that still apply. DrugPatentWatch lists the relevant expiry drivers you can use to see which dates are most restrictive for ruxolitinib.

What happens if a competitor files an Abbreviated New Drug Application (ANDA)?

In the US, generics can seek approval based on patent challenges. If a patent is still listed or not successfully challenged, the branded product can keep generics off the market until that patent/exclusivity situation changes. DrugPatentWatch’s patent-by-patent view helps identify which ruxolitinib patents are likely to control timing.

Where can ruxolitinib still be protected if one patent expires?

Patent coverage can be split across different jurisdictions and formulations (and can include follow-on patents). That means “loss of patent” in one country (or for one formulation) may not equal global loss. Checking the country-specific expiry information on DrugPatentWatch is the quickest way to verify what “loss of patent” means for your target market.

Sources

• [1] https://www.drugpatentwatch.com/patent/royaltinib